The Rationality of Implementation of Dimethyl Sulfoxide As Differentiation-inducing Agent in Cancer Therapy

Overview

Journal Cancer Diagn Progn

Specialty Oncology

Date 2023 Jan 12

PMID 36632588

Authors

Ba X Hoang

B O Han

William H Fang

Hau D Tran

Cuong Hoang

David G Shaw

Thai Q Nguyen

Affiliations

Soon will be listed here.

Abstract

One of the major hallmarks of many cancer cells is dedifferentiated cells (immature cells) with little or no resemblance to normal cells. Besides the poor differentiation, malignant cells also have important features such as aggressiveness and resistance to different therapeutics. Differentiation potentiators hold great promise for cancer treatment. Dimethyl sulfoxide (DMSO) is a well-characterized pharmaceutical solvent. It is used as a component of numerous cancer therapeutic approaches, including cancer treatment and several approved cancer immune therapeutics such as Car-T cell therapy and the FDA-approved drug Mekinist (trametinib DMSO) for melanoma treatment. It is also biologically recognized as a pharmaceutical solvent and cryoprotectant. In the current literature, there are no mentions of DMSO's possible ability to potentiate therapeutic activity as a component of these cancer treatments. This review aimed to summarize scientific evidence and substantiate the concept that DMSO can contribute positively to the overall efficacy of cancer treatment as an adjuvant that is safe, inexpensive, and an effective differentiation-inducing therapeutic agent.

Citing Articles

Alternative Cancer Therapeutics: Unpatentable Compounds and Their Potential in Oncology.

Ovcharenko D, Mukhin D, Ovcharenko G Pharmaceutics. 2024; 16(9).

PMID: 39339273 PMC: 11435428. DOI: 10.3390/pharmaceutics16091237.

The effect of DMSO on Saccharomyces cerevisiae yeast with different energy metabolism and antioxidant status.

Swiecilo A, Janus E, Krzepilko A, Skowronska M Sci Rep. 2024; 14(1):21974.

PMID: 39304697 PMC: 11415381. DOI: 10.1038/s41598-024-72400-4.

A Prospective Study of AFree Oral Spray as an Adjuvant Therapy for Mild and Moderate COVID-19 in Community Health Stations: Clinical Progression and Viral Clearance Outcomes.

Tran D, Pham T, Nguyen N, Tran H, Hoang H, Han B In Vivo. 2023; 37(5):2155-2160.

PMID: 37652493 PMC: 10500509. DOI: 10.21873/invivo.13313.

Detection of Treatment Response in Triple-Negative Breast Tumors to Paclitaxel Using MRI Cell Size Imaging.

Jiang X, McKinley E, Xie J, Gore J, Xu J J Magn Reson Imaging. 2023; 59(2):575-584.

PMID: 37218596 PMC: 10665540. DOI: 10.1002/jmri.28774.

References

Grunt T, Somay C, Oeller H, Dittrich E, Dittrich C . Comparative analysis of the effects of dimethyl sulfoxide and retinoic acid on the antigenic pattern of human ovarian adenocarcinoma cells. J Cell Sci. 1992; 103 ( Pt 2):501-9. DOI: 10.1242/jcs.103.2.501. View

Waller F, Tanabe C, PAXTON H . Treatment of elevated intracranial pressure with dimethyl sulfoxide. Ann N Y Acad Sci. 1983; 411:286-92. DOI: 10.1111/j.1749-6632.1983.tb47310.x. View

Hoang B, Tran H, Vu U, Pham Q, Shaw D . Palliative treatment for advanced biliary adenocarcinomas with combination dimethyl sulfoxide-sodium bicarbonate infusion and S-adenosyl-L-methionine. J Pain Palliat Care Pharmacother. 2014; 28(3):206-11. DOI: 10.3109/15360288.2014.938882. View

Jiang Z, Zhang H, Wang Y, Yu B, Wang C, Liu C . Altered Hepa1-6 cells by dimethyl sulfoxide (DMSO)-treatment induce anti-tumor immunity in vivo. Oncotarget. 2016; 7(8):9340-52. PMC: 4891044. DOI: 10.18632/oncotarget.7009. View

Goto I, Honma Y . Enhancement of sensitivity of human lung adenocarcinoma cells to growth-inhibitory activity of interferon alpha by differentiation-inducing agents. Br J Cancer. 1996; 74(4):546-54. PMC: 2074667. DOI: 10.1038/bjc.1996.399. View

Edelson J, Shannon J, Mason R . Alkaline phosphatase: a marker of alveolar type II cell differentiation. Am Rev Respir Dis. 1988; 138(5):1268-75. DOI: 10.1164/ajrccm/138.5.1268. View

Yan M, Liu Q . Differentiation therapy: a promising strategy for cancer treatment. Chin J Cancer. 2016; 35:3. PMC: 4704415. DOI: 10.1186/s40880-015-0059-x. View

Simon L, Grierson L, Naseer Z, Bookman A, Shainhouse Z . Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. Pain. 2009; 143(3):238-245. DOI: 10.1016/j.pain.2009.03.008. View

Brayton C . Dimethyl sulfoxide (DMSO): a review. Cornell Vet. 1986; 76(1):61-90. View

10.

Tsao D, Morita A, Bella Jr A, Luu P, Kim Y . Differential effects of sodium butyrate, dimethyl sulfoxide, and retinoic acid on membrane-associated antigen, enzymes, and glycoproteins of human rectal adenocarcinoma cells. Cancer Res. 1982; 42(3):1052-8. View

11.

Grunt T, Somay C, Pavelka M, Ellinger A, Dittrich E, Dittrich C . The effects of dimethyl sulfoxide and retinoic acid on the cell growth and the phenotype of ovarian cancer cells. J Cell Sci. 1991; 100 ( Pt 3):657-66. DOI: 10.1242/jcs.100.3.657. View

12.

Hoang B, Levine S, Shaw D, Tran D, Tran H, Nguyen P . Dimethyl sulfoxide as an excitatory modulator and its possible role in cancer pain management. Inflamm Allergy Drug Targets. 2010; 9(4):306-12. DOI: 10.2174/187152810793358732. View

13.

Rowley S, Baer R . Lens deposits associated with RIMSO-50 (dimethylsulphoxide). Eye (Lond). 2001; 15(Pt 3):332-3. DOI: 10.1038/eye.2001.107. View

14.

Enane F, Saunthararajah Y, Korc M . Differentiation therapy and the mechanisms that terminate cancer cell proliferation without harming normal cells. Cell Death Dis. 2018; 9(9):912. PMC: 6127320. DOI: 10.1038/s41419-018-0919-9. View

15.

Salim A . Protection against stress-induced acute gastric mucosal injury by free radical scavengers. Intensive Care Med. 1991; 17(8):455-60. DOI: 10.1007/BF01690766. View

16.

BREITMAN T, He R . Combinations of retinoic acid with either sodium butyrate, dimethyl sulfoxide, or hexamethylene bisacetamide synergistically induce differentiation of the human myeloid leukemia cell line HL60. Cancer Res. 1990; 50(19):6268-73. View

17.

Kawamata H, Tachibana M, Fujimori T, Imai Y . Differentiation-inducing therapy for solid tumors. Curr Pharm Des. 2006; 12(3):379-85. DOI: 10.2174/138161206775201947. View

18.

Hong C, Ahn B . Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer for Reapplication of I-131 Therapy. Front Endocrinol (Lausanne). 2017; 8:260. PMC: 5649198. DOI: 10.3389/fendo.2017.00260. View

19.

Morassi P, Massa F, Mesesnel E, MAGRIS D, DAGNOLO B . [Treatment of amyloidosis with dimethyl sulfoxide (DMSO)]. Minerva Med. 1989; 80(1):65-70. View

20.

Lee Y, Shim H, Yu H, Song E, Park J, Kwon K . Dimethylsulfoxide induces upregulation of tumor suppressor protein PTEN through nuclear factor-kappaB activation in HL-60 cells. Leuk Res. 2005; 29(4):401-5. DOI: 10.1016/j.leukres.2004.09.010. View